Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up **Abstract #:** at Time of Venetoclax Initiation for CLL: A Real-World Experience 1529308



Grace Baek^{1,2}, Ivan Huang^{1,2}, Jonathan Cohen^{1,2}, Sirin Khajaviyan¹, Stephanie Louie¹, Laura Samples^{1,2}, Stephen Smith^{1,2}, Brian Till^{1,2}, Houston Warren^{1,2}, Ajay Gopal^{1,2}, Christina Poh^{1,2}, Ryan Lynch^{1,2}, Chaitra Ujjani^{1,2}, Mazyar Shadman^{1,2} ¹Fred Hutchinson Cancer Center, Seattle, WA; ²UW Medicine, Seattle, WA

BACKGROUND

- Venetoclax has become a standard of care for chronic lymphocytic leukemia (CLL)/small lymphocytic lyr (SLL) as one of several preferred treatment options for newly diagnosed or relapsed/refractory disease without del(17p)/TP53 mutation.^{1,2}
- Significant risk of clinical tumor lysis syndrome (TLS) a potentially fatal complication characterized by hyperuricemia, extreme electrolyte abnormalities, and related complications such as acute kidney failur been previously well characterized for B-cell directed therapies in CLL/SLL.^{3,4,5}
- Given the risk of TLS observed in early-phase development, venetoclax initiation for CLL/SLL includes a week venetoclax ramp-up schedule as the labeled/standard dosing schema, as well as scrupulous suppo care measures and monitoring.^{2,3,4,6} It is recommended that patients at highest risk for TLS be admitted close observation, but use of the standard ramp-up schedule in ambulatory care settings has demonstra safety and effectiveness for the majority of patients.^{6,7}
- The requirements for intensive monitoring, which require frequent patient visits, is a limiting factor that contributed to the relatively low utilization of this effective drug.
- Prior characterization of TLS events demonstrate occurrence most frequently within the first week of the
- The clinical relevance of such intensive monitoring for venetoclax in clinical practice, especially in patier low or medium risk for TLS, is unknown. Alternative ramp-up schedules for venetoclax are being investig

OBJECTIVES

- Evaluate real-world incidence of clinical and laboratory TLS in CLL/SLL patients undergoing standard ven ramp-up to elucidate at-risk sub-populations and identify opportunities to optimize venetoclax ramp-up
- Offer insight as to evolving best practices for intensive monitoring and logistics required with initiation therapy, a potentially limiting constraint for patients and providers compared to alternative therapies.

METHODS

STUDY DESIGN


- IRB-approved, single-center, retrospective study
- Clinical interventions reported for laboratory or clinical findings were documented for each week of the ra

DEFINITIONS


- TLS: Cairo-Bishop criteria¹⁰
- Laboratory abnormalities: based on absolute threshold

PRIMARY ENDPOINT

Incidence of laboratory and clinical TLS and clinical interventions that were done based on laboratory find during the ramp-up



PATIENT SCREENING AND EXCLUSION



	Lab TLS <i>,</i> n(%)	Clinical TLS, n(%)		Any clinical intervention, n(%)	IV fluids, n(%)	Intervention other than IV fluids, n(%)	
Week 1, Day 1 ^Δ	1 (1.8%)	0	Week 1, Day 1 ^Δ	1 (1.8%)	0	1 (1.8%)*	
Week 1, Day 2	0	0	Week 1, Day 2	1 (1.8%)	0	1 (1.8%)*	
Week 2	0	0	Week 2	2 (3.6%)	0	2 (3.6%)*,**	
Week 3	0	0	Week 3	1 (1.8%)	0	1 (1.8%)*	
Week 4	0	0	Week 4	1 (1.8%)	1 (1.8%)	0	
Week 5	0	0	Week 5	0	0	0	
VVEEK J							_
Total Events Abbreviations: IV, intrave Criteria f	or labora	itory TLS w	Total Events ay 1, after initiating venetoclax ramp-up ; *Received phos vere met with 1 patient (1. medium and high TLS risk	8%) overall		5 (across 2 patients)	
Total Events Abbreviations: IV, intrave • Criteria f • No lab of Excluded from d • Laboratory de	or labora r clinical <i>clinical</i> <i>clinical</i> <i>clinical</i> <i>clinical</i> <i>clinical</i>	sis syndrome. [Δ On da tory TLS w TLS in the normal limits b	ay 1, <u>after</u> initiating venetoclax ramp-up ; *Received phos	phate-lowering intervention ; **Receive 8%) overall patient populatio			

Two patients (both relapsed/reliactory disease) completed 5-week ramp-up at a mai dose of venetociax 200 mg dally: One due to hypoca, hyperphos, and hyperk 🗁 added fv fluids; one with new-onset knee/tailbone pain, achiness, and sweats.

CONCLUSIONS

- Intensive laboratory monitoring during the 5-week ramp-up in CLL/SLL patients with majority low or medium-risk TLS risk resulted in very low rates of laboratory and clinical TLS, as well as clinical interventions. These rates in a predominantly newly diagnosed patient population were similar, or lower than, previously reported real-world results, which were often reported with r/r CLL patients.
- Higher TLS risk did not translate into higher incidence of laboratory or clinical TLS.
- No episodes of laboratory or clinical TLS occurred among our newly diagnosed patient sub-population. Newly diagnosed CLL/SLL patients with prior debulking therapy may be candidates for less intensive laboratory monitoring during venetoclax ramp-up.
- Further research into strategies to de-intensify laboratory monitoring requirements and abbreviate venetoclax ramp-up for CLL/SLL should be considered. This may potentially increase the utilization of venetoclax.



E	Μ	0	G	R	Α	P	HI	

DEMOGRAPHICS					
(N=56)					
Age					
Median (IQR)	64 (58,70)				
Min-Max	39-81				
Sex, n(%)					
Male	42 (75)				
Female	14 (25)				
TLS Risk, n(%)					
Low	42 (75)				
Intermediate	13 (23)				
High	1 (2)				
Line of Therapy					
Median (IQR)	0 (0, 1)				
Min-Max	0, 5				
Prior Debulking Therapy, n(%)					
Total	46 (82)				
Obinutuzumab	21 (46)				
Rituximab	25 (53)				
CLL Risk (Pre-Treatment), n(%)					
Favorable	27 (48.2)				
Intermediate	10 (17.8)				
Unfavorable	18 (32)				
Not available	1 (2)				
TLS Prophylaxis, n(%)					
Any oral anti-hyperuricemic agent	56 (100)				
Allopurinol	55 (98)				
Febuxostat	1 (2)				
IV Fluids					
Week 1	40 (73)				
Week 2	31 (55)				
Week 3	19 (34)				
Week 4	11 (20)				
Week 5	11 (20)				
Creatinine Clearance, mL/min					
Median (IQR)	89.2 (69.7, 129.85)				
Abbreviations: IV intravenous: TLS tumor lysis syndrome	14, 224.1				
Abbreviations: IV, intravenous; TLS, tumor lysis syndrome					

1.	NCCN Guidelines: Chronic Lymphocytic
2.	Venetoclax tablets [package insert]. Rev
3.	Cheson BD, Enschede SH, Cerri E, et al.
4.	Fischer K, Al-Sawaf O, and Hallek M. Pre
	leukemia. Hematology. 2020;(1):357-36
5.	Gribben J. Practical management of tun
6.	Figueroa-Mora R, Rampotas A, Halperir
	retrospective study. Br J Haematol. 202
7.	Sharman J, Biondo J, Boyer M, et al. A r
	strategies. EJHaem. 2022;3(2):492-506.
8.	Stilgenbauer S, Eichhorst B, Schetelig J,
	Lancet Oncol. 2016;17(6):768-778.
9.	Koenig K, Huang Y, Dotson E, et al. Safe
	2020;4(19):4860-4863.
10.	Cairo MS and Bishop M. Tumour lysis sy
11.	Figueroa-Mora R, Rampotas A, Halperir
	retrospective study. BJHaem. 2023;202
12.	Lee C, Markarian A, Ladha F, et al. Real-
13.	Matuszfisher A, Bose R, Boselli D, et al.
	in the Real-World Setting- Suggests Les
14.	Koehler A, Leung N, Call TG, et al. Incide
	clinical practice. Leuk Lymphoma. 2020;
15.	Mato AR, Thompson M, Allan JN, et al.
	Haematologica. 2081;103(9):1511-1517



Correspondence should be addressed to: gbaek@fredhutch.org

UWMedicine

Leukemia/Small Lymphocytic Lymphoma. Version 3.2023 ised 6/2022. AbbVie Inc: North Chicago. I

Fumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents, *The Oncologist*, 2017; 22(11):1283-1291 venting and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic nour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Br J Haematol. 2020;188:844-851.

n D. et al. Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom; a real world multicentry

d or refractory chronic lymphocytic leukaemia with 17p deletion; a multicentre, open-label, phase 2 study y of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. Blood Adv

ndrome: new therapeutic strategies and classification Br I Haematol 2004.127(1):3-7

D. et al. Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentu

very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax Intensive Monitoring Maybe Safe for Low-Risk Patients, *Blood* [abstract], 2021; 138(1); 1557 nce and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine :61(10):2383-2388 Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States